1 / 6

Design Of Nanoparticular Carriers Targeting Toll Like Receptors For Vaccine Purpose

Design Of Nanoparticular Carriers Targeting Toll Like Receptors For Vaccine Purpose. XVIII International AIDS Conference 18 – 23 July 2010 Vienna, Austria. Vincent Pavot UMR 5086 CNRS/UCBL LYON (France) Bernard Verrier group. In vivo administration.

fisk
Télécharger la présentation

Design Of Nanoparticular Carriers Targeting Toll Like Receptors For Vaccine Purpose

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Design Of Nanoparticular Carriers TargetingTollLikeReceptors For Vaccine Purpose XVIII International AIDS Conference 18 – 23 July 2010 Vienna, Austria Vincent Pavot UMR 5086 CNRS/UCBL LYON (France) Bernard Verrier group

  2. In vivo administration • Particulate delivery-systems based on biodegradable polymers induction of broad humoral and cellular immune responses. • TLR are involved in innate immune response co delivering of an antigen and a TLR agonist amplify immune response against this antigen. We hypothesize that the adjunction of a co-stimulatory molecule TLR-3 agonist (poly(I:C)) will be a way of co-adjuvantation of p24 when co delivered by particles of either PLA (PolyLactic Acid) or Chitosan. p24 adorption on nacked NPs TLR agonist co-adsorption Y Y Y Y Sample collection: blood, feces and vaginal washes To analyze antibodies : - Serum IgG - Mucosal SIgA (faecaland vaginal) Humoral responseanalysis

  3. High IgG HIV-p24 titre in sera SerumIgG titre W0 W2 W4 W6 p24 PLA-p24 Chito +P24 p24+ Poly(I:C) PLA-p24 + Chito PLA-p24 + Poly(I:C) Chito-Poly(I:C) + p24 PLA-p24 + Chito-Poly(I:C) • PLA-p24 >> p24 alone. • The quickest and more efficient systemic immune response is observed with Chitosan-Poly(I:C) + p24.

  4. Mucosal immune responses Vaginal IgA W0 Vaginal IgG D.O. W2 W4 W6 D.O. p24 PLA-p24 Chito + p24 p24 + Poly(I:C) PLA-p24 + Poly(I:C) PLA-p24 + Chito Chito-Poly(I:C) + p24 PLA-p24 + Chito-Poly(I:C) p24 PLA-p24 Chito + p24 p24 + Poly(I:C) PLA-p24 + Chito-Poly(I:C) Chito-Poly(I:C) + p24 PLA-p24 + Poly(I:C) PLA-p24 + Chito • No specific induction of p24 immune responses in mucosal sites (vaginal and intestinal).

  5. Conclusions • Subcutaneous administration of NPs-p24 induce quick and high systemic immune response. • The quickest and more efficient systemic immune response is observed with Chitosan-Poly(I:C) + p24. • Subcutaneous administration does not induce mucosal immune response. • Results in mucosa could be explained by a non optimum dose of poly(I:C). • - Try with different doses of poly(I:C) • - Try with different adjuvant molecules (TLR-7, -8, NODs ligands,…) • Try other routes of administration: oral, vaginal, intranasal, … • Try a prime-boost strategy (combine with viral vectors). Adjunction of a co-stimulatory molecule TLR-3 agonist (poly(I:C)) with p24 co delivered by nanoparticles of chitosan amplify systemic immune response against p24.

  6. Acknowledgement

More Related